Effect of anti-rheumatic drugs on the clinical outcome of autoimmune rheumatic diseases patients infected with COVID-19: A systemic review and meta-analysis

The immune deregulation and disease-modifying anti-rheumatic drugs (DMARDs) make patients with autoimmune rheumatic diseases (ARD) more susceptible to infection. We aimed to investigate the prevalence and clinical outcome of COVID-19 in ARD patients with different treatments. PubMed, Embase, Medline, Cochrane Library, Web of Science were searched to identify the relevant evidence up to March 20, 2023. The overall prevalence of COVID-19 in ARD patients was 0.061. The ARD patients with glucocorticoids (GC) treatment had the highest prevalence[0.088(95%CI:0.065-0.110)] compared to biological (b) DMARDs[0.041(95%CI:0.031-0.051

[1]  Dilek Karadoğan,et al.  Management of Patients with Connective Tissue Disease-associated Interstitial Lung Diseases During the COVID-19 Pandemic. , 2021, Turkish thoracic journal.

[2]  Z. Wallace,et al.  COVID-19 and Disease-Modifying Anti-rheumatic Drugs , 2021, Current Rheumatology Reports.

[3]  Mohammed Hjouj,et al.  Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2020(COVID-19) in Palestine: A Report of 200 Cases , 2021 .

[4]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[5]  E. Pelechas,et al.  Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience , 2021, Rheumatology International.

[6]  P. Sarbakhsh,et al.  Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis , 2021, European Journal of Pharmacology.

[7]  L. Trupin,et al.  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2021, Annals of the Rheumatic Diseases.

[8]  M. Kappelman,et al.  Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry , 2021, Gastroenterology.

[9]  C. Yeh,et al.  Epidemiology changes in peptic ulcer diseases 18 years apart explored from the genetic aspects of Helicobacter pylori. , 2020, Translational research : the journal of laboratory and clinical medicine.

[10]  T. Niewold,et al.  COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease , 2020, Translational Research.

[11]  L. Magder,et al.  Impact of Sex and Metabolic Comorbidities on Coronavirus Disease 2019 (COVID-19) Mortality Risk Across Age Groups: 66 646 Inpatients Across 613 U.S. Hospitals , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Feldmann,et al.  The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19 , 2020, Med.

[13]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[14]  S. Feldman,et al.  Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study , 2020, Journal of Allergy and Clinical Immunology.

[15]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[16]  B. Himes,et al.  Insights into glucocorticoid responses derived from omics studies. , 2020, Pharmacology & therapeutics.

[17]  Kelsey K. Finn,et al.  Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.

[18]  P. Robinson,et al.  Management of autoimmune disease during the COVID-19 pandemic , 2020, Australian prescriber.

[19]  A. Ogdie,et al.  COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes , 2020, Arthritis & rheumatology.

[20]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.

[21]  Ömer Kutlu,et al.  Psoriasis and COVID‐19: A narrative review with treatment considerations , 2020, Dermatologic therapy.

[22]  A. Manenti,et al.  Type 3 hypersensitivity in COVID-19 vasculitis , 2020, Clinical Immunology.

[23]  S. Ng,et al.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.

[24]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[25]  John D. Lambris,et al.  The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 , 2020, Clinical Immunology.

[26]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  K. Syrigos,et al.  Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action , 2020, British journal of haematology.

[28]  C. Montecucco,et al.  Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.

[29]  F. Ingegnoli,et al.  COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.

[30]  Hong Jiang,et al.  Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up , 2020, Journal of Infection.

[31]  Q. Tao,et al.  Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases , 2020, Radiology.

[32]  Yicheng Fang,et al.  Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR , 2020, Radiology.

[33]  W. Cao,et al.  Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia , 2020, Emerging microbes & infections.

[34]  P. Borgiani,et al.  Interaction between microbiome and host genetics in psoriatic arthritis. , 2018, Autoimmunity reviews.

[35]  C. Libert,et al.  Therapeutic Mechanisms of Glucocorticoids , 2018, Trends in Endocrinology & Metabolism.

[36]  Patty J. Lee,et al.  Aging Enhances the Basal Production of IL-6 and CCL2 in Vascular Smooth Muscle Cells , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[37]  J. Carter,et al.  Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Secondary to Infliximab , 2003, Journal of clinical gastroenterology.

[38]  C. Janeway.  Immunobiology: The Immune System in Health and Disease , 1996 .

[39]  S. Raychaudhuri,et al.  Functional significance of MAIT cells in psoriatic arthritis. , 2019, Cytokine.

[40]  J. Listing,et al.  The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. , 2013, Rheumatology.